J Kelly1, H P Redmond. 1. Department of Academic Surgery, Cork University Hospital, Cork, Ireland. justinjoshkelly@gmail.com
Abstract
INTRODUCTION: The natural history of metastatic melanoma involving lymph nodes, in the absence of a known primary site (cutaneous, ocular or mucosal) has, to date, been poorly defined; and the optimal management of this rare subtype of disease is therefore unclear. Melanomas of unknown primary site (MUP) are estimated to comprise between 3.7 and 6% of all melanomas (Anbari et al. in Cancer 79:1861-1821, 1997). MATERIALS AND METHODS: Between 2002 and 2007, 478 patients were treated for melanoma in our department in Cork University Hospital, five of whom presented with MUP. We discuss their cases herein. CONCLUSION: We should continue to treat this cohort of patients with an aggressive surgical approach and consider them for adjuvant therapies currently used to treat stage III disease.
INTRODUCTION: The natural history of metastatic melanoma involving lymph nodes, in the absence of a known primary site (cutaneous, ocular or mucosal) has, to date, been poorly defined; and the optimal management of this rare subtype of disease is therefore unclear. Melanomas of unknown primary site (MUP) are estimated to comprise between 3.7 and 6% of all melanomas (Anbari et al. in Cancer 79:1861-1821, 1997). MATERIALS AND METHODS: Between 2002 and 2007, 478 patients were treated for melanoma in our department in Cork University Hospital, five of whom presented with MUP. We discuss their cases herein. CONCLUSION: We should continue to treat this cohort of patients with an aggressive surgical approach and consider them for adjuvant therapies currently used to treat stage III disease.
Authors: A Eigtved; A P Andersson; K Dahlstrøm; A Rabøl; M Jensen; S Holm; S S Sørensen; K T Drzewiecki; L Højgaard; L Friberg Journal: Eur J Nucl Med Date: 2000-01
Authors: Kenneth A Katz; Eric Jonasch; F Stephen Hodi; Robert Soiffer; Kimberly Kwitkiwski; Arthur J Sober; Frank G Haluska Journal: Melanoma Res Date: 2005-02 Impact factor: 3.599
Authors: B Schlagenhauff; W Stroebel; U Ellwanger; F Meier; C Zimmermann; H Breuninger; G Rassner; C Garbe Journal: Cancer Date: 1997-07-01 Impact factor: 6.860
Authors: J M Kirkwood; J G Ibrahim; V K Sondak; J Richards; L E Flaherty; M S Ernstoff; T J Smith; U Rao; M Steele; R H Blum Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544
Authors: K K Anbari; L M Schuchter; L P Bucky; R Mick; M Synnestvedt; D Guerry; R Hamilton; A C Halpern Journal: Cancer Date: 1997-05-01 Impact factor: 6.860